Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Inari Medical Are Falling Today

By Jason Hawthorne – Aug 11, 2021 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dollars outpaced procedures in the second quarter.

What happened

Shares of Inari Medical (NARI -2.06%) were down almost 16% as of 11:25 a.m. EDT today, after the company reported earnings yesterday that seemed impressive at first glance. After digging a little deeper, Wall Street found a few concerns.

So what

The company's clot removal devices continue to drive exceptional sales. Revenue for the second quarter climbed 150%, and overall procedure growth came in at 136%. That slight difference might be what raised a yellow flag.

Medical professionals working in an intensive care unit.

Image source: Getty Images.

CEO Bill Hoffman pointed to the declining prevalence of COVID-19 -- which can cause blood clots in the veins -- as the primary reason behind the lagging procedure numbers. About 15% of patients treated in the first two months of the year had the disease. By June, that number was down to 4%. The disconnect is more pronounced in the sequential numbers.

Compared with the first quarter of 2021, revenue and procedures grew 10.6% and 7.3%, respectively. That sequential procedure growth has declined every quarter since last fall, when it was 52.5%. 

Now what

It's the first wrinkle in the growth story for the company since it went public in May of last year. Shares are still up 75% since then, but down 40% from all-time highs.

Management estimated full-year revenue will be between $250 million to $255 million. That's up a few percent from previous guidance despite a cautionary comment about physicians and hospital staff taking vacations in the third quarter. 

As for tailwinds, the company continued building out sales territories as planned and received regulatory approval for its new FlowSaver device. With hospitalizations for COVID-19 more than tripling in just the past month, the procedure numbers are likely to pick back up through the rest of the year. It will be interesting to see if the market reverses the punishment it is handing out today if that happens.

Jason Hawthorne owns shares of Inari Medical, Inc. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inari Medical, Inc. Stock Quote
Inari Medical, Inc.
NARI
$72.31 (-2.06%) $-1.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.